Abstract | INTRODUCTION: METHODS: RESULTS: The mRNA expression of FSTL1 was significantly increased in LPS-treated BEAS-2B cells. Silencing of FSTL1 inhibited the release of IL-6, IL-8, TNF-α, and cell apoptosis as well as enhanced the activities of SOD, CAT, and GSH-Px. Silencing of FSTL1 reversed the inflammatory state of cells by upregulating BMP4 and increasing the expression level of KLF4. CONCLUSION: Silencing of FSTL1 reduced LPS-induced BEAS-2B cell damage by regulating the BMP4/KLF4 axis. FSTL1 may be a potential target for the treatment of asthma.
|
Authors | Yi Zhang, Liping Yan, Jiao Yang, Xiangni Li |
Journal | International archives of allergy and immunology
(Int Arch Allergy Immunol)
Vol. 183
Issue 7
Pg. 785-795
( 2022)
ISSN: 1423-0097 [Electronic] Switzerland |
PMID | 35390783
(Publication Type: Journal Article)
|
Copyright | © 2022 S. Karger AG, Basel. |
Chemical References |
- BMP4 protein, human
- Bone Morphogenetic Protein 4
- Follistatin-Related Proteins
- Interleukin-6
- Interleukin-8
- KLF4 protein, human
- Kruppel-Like Factor 4
- Lipopolysaccharides
- Tumor Necrosis Factor-alpha
- FSTL1 protein, human
- Superoxide Dismutase
|
Topics |
- Asthma
(genetics, metabolism)
- Bone Morphogenetic Protein 4
(genetics, metabolism)
- Child
- Epithelial Cells
(metabolism)
- Follistatin-Related Proteins
(genetics, metabolism)
- Gene Silencing
- Humans
- Inflammation
(metabolism)
- Interleukin-6
(metabolism)
- Interleukin-8
(metabolism)
- Kruppel-Like Factor 4
(genetics, metabolism)
- Lipopolysaccharides
(pharmacology)
- Oxidative Stress
- Superoxide Dismutase
- Tumor Necrosis Factor-alpha
(metabolism)
|